Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) launched the phase III clinical trial of the lyophilized live attenuated varicella vaccine (VZV-7D), according to a Shanghai bourse disclosure on Friday.
The Chinese pharmaceutical company enrolled the first subject for the study of the vaccine, which helps boost the immune system against the varicella-zoster virus.